The percentages of CD45+CD3+CD69+ cells were increased from 1.61% to 34.3% in healthy volunteers’ group and from 1.9% to 81.2% in the NSCLC patients’ group. This evidence concerns the gene PTPRC and non-small cell lung carcinoma.